CluePoints Strengthens and Expands Global Team
News Feb 26, 2014
CluePoints has announced three new appointments to its global team. John Colby and Elizabeth Polvent join the company's U.S business development team, fulfilling a key element in its strategy for growth, while CluePoints also welcomes Jean Stéphenne, President of the Board of Directors of GlaxoSmithKline Biologicals, as a member of its board.
John Colby joins CluePoints as Senior Director of Business Development on the East Coast U.S, providing strategic leadership and driving business growth in the geography.
Previously of Aptiv Solutions and PRA International, John brings a strong track record of managing strategic relationships in the clinical trials industry.
Elizabeth Polvent has been named as the company's Director of Business Development on the West Coast. Based in California, she has more than 10 years' Clinical Operations experience in the industry with her most recent roles serving as the key liaison on Federally funded clinical trials, as well as overseeing early-phase clinical development programs. She joins CluePoints to support the growth of the business' footprint and to establish long-term partnerships with key customers in the region.
In addition to strengthening its business development team, CluePoints has announced that Jean Stéphenne has joined the company's board of directors. Jean joined SmithKline-RIT (now GSK Biologicals) in 1974 as head of bacterial and viral vaccines production.
Through various executive management positions within the company, he has led GSK's global vaccines business since 1988. From March 2010 to April 2012, he was appointed as the Chairman and President of GSK Biologicals.
Jean currently serves as a Special Advisor to the CEO at GSK, is a member of the Corporate Executive Team (GSK Group), as well as President of the Board of Directors of GSK Biologicals.
"CluePoints is at a very exciting time in its development with increasing demand for its solutions as a result of growing regulatory support for practical Risk-Based Monitoring techniques," comments Jean Stéphenne. He adds, "With a steadily growing global reputation for delivering scientific excellence and innovation, CluePoints is making its mark on the industry and I am delighted to be joining the company's board and look forward to the opportunity to help build on its achievements."
Francois Torche, CEO of CluePoints, comments: "I am delighted to announce the three new additions to our global team. In 2014 CluePoints is focused on fulfilling demand in growing markets and achieving new levels of innovation for customers. I believe the insights and experience of each of these new appointments will be invaluable in our ongoing development."
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Anti-Malaria Drugs Delivered With CaffeineNews
Many drug delivery systems, such as capsules and tablets, can be difficult to swallow, especially for children. Making delivery systems out of polymer gels is an attractive option, but usually requires hazardous levels of heavy metals to be used. Now, scientists have found a way to build these gels from caffeine molecules.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
Comments | 0 ADD COMMENT
2nd International Conference and Exhibition on Nanomedicine and Drug Delivery
May 21 - May 23, 2018
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018